Drug intelligence / Profile preview

Vasa-1

Development stage: Unknown
Lead developer: Vasa Therapeutics
Modality: Small Molecules

Overview

Vasa-1 (also known as VT1) is a clinical-stage therapeutic candidate being developed by Orphinic Scientific for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) and diastolic heart failure. The drug utilizes a proprietary scaffold to target matrix metalloproteinases (MMPs), a family of enzymes involved in the remodeling of the cardiac extracellular matrix. In HFpEF, maladaptive MMP activity contributes to myocardial fibrosis and structural changes that impair cardiac relaxation and filling. By inhibiting MMP activity, Vasa-1 aims to mitigate these fibrotic processes and improve diastolic function, addressing a significant unmet need in cardiovascular medicine.

Other names: VT1VT-1VT 1

Targets

MMP9 (Matrix metalloproteinase-9)MMP13 (Matrix metalloproteinase-13)MMP2 (Matrix metalloproteinase-2)

Beyond the preview

Go deeper on Vasa-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vasa-1.

Explore the full profile